Harrow Health Inc (HROW)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.13B
Last updated: Nov 17, 2026 at 11:05 AM ET
Harrow Health Inc (HROW) Valuation Multiples
Harrow Health (HROW) trades at 3.6x sales and 37.4x book value. Its P/S of 3.6x is below its 5-year median of 4.7x. Its forward P/E is 41.8x.
Current Multiples
Its enterprise value is 57.4x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 41.8x |
| Price to sales | 3.6x |
| Price to book | 37.4x |
| EV/EBITDA | 57.4x |
| PEG | N/A |
| FCF yield | -1.9% |
Historical Medians
Against its 10-year medians, its P/S is 2.9% above 3.5x and its P/B is 157.9% above 14.5x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.6x | 4.7x | 3.5x |
| P/B | 37.4x | 24.1x | 14.5x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.3x in 2017 to 6.6x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $49.00 | 107.1x | 6.6x | 34.3x |
| 2024 | $33.55 | N/A | 6.0x | 17.2x |
| 2023 | $11.20 | N/A | 2.8x | 5.6x |
| 2022 | $14.76 | N/A | 4.6x | 15.9x |
| 2021 | $8.64 | N/A | 3.2x | 21.0x |
| 2020 | $6.86 | N/A | 3.6x | 6.5x |
| 2019 | $7.78 | N/A | 3.9x | 7.3x |
| 2018 | $5.69 | 9.6x | 3.1x | 5.6x |
| 2017 | $1.70 | N/A | 1.3x | 13.6x |
| 2016 | $2.50 | N/A | 1.7x | 7.4x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HROW
What is HROW's forward P/E ratio?
Harrow Health has a forward P/E ratio of 41.8x.
Is HROW stock overvalued?
GNG's valuation label for HROW is Fairly valued.
What is HROW's price to sales ratio?
Harrow Health has a price to sales ratio of 3.6x.
HROW pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors